VTRS at a glance
Viatris (VTRS, SEC CIK 1792044) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Viatris (VTRS) reported revenue of $14.3 billion (down 3.0% from FY2024) and a net loss of $3.5 billion. Diluted EPS was -$3.00.
- As of June 30, 2026, 48 institutional investment managers tracked by SignalX reported holding Viatris (VTRS) shares worth $9.5 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $14.3B
- −3.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 48 funds
- $9.5B · +2 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 8.01 · Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Global pharma company delivering generics, branded generics, and innovative medicines to ~1B patients across 165+ countries with 30,000+ employees and 27 manufacturing sites
- Five positive Phase 3 readouts in 2025: meloxicam acute pain, low-dose estrogen patch (FDA action target July 30, 2026), LYNX-2 night driving (MR-142), VEGA-3 presbyopia (MR-141, FDA action H2 2026), and EFFEXOR Japan GAD
- EWSR launched 2025: up to ~10% global workforce reduction, $700M–$850M in restructuring charges, targeting $600M–$700M in savings once fully implemented
- 2025 total revenues $14.30B; returned >$1B to shareholders (~$500M buybacks + $561M dividends) despite divestiture headwinds and Indore FDA warning letter impact
- Acquired Aculys Pharma (Oct 2025) for Japan-exclusive rights to pitolisant (narcolepsy/sleep apnea) and Spydia® Nasal Spray: sharpest pivot yet toward patent-protected innovative assets in Japan
Risk Factors
- FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025
- U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected
- Top 3 customers ~25% of net sales; limited manufacturing sites plus post-divestiture API supply dependence on single external vendor
- Inflation Reduction Act (2022) drug price negotiation and most-favored-nation pilot programs risk compressing innovative pipeline product margins
- Significant indebtedness with refinancing risk at higher rates; $2.94B goodwill impairment charge taken in 2025
Management Discussion & Analysis
- Revenue $14.30B, down 3% YoY ($439M decline); Indore facility impact ~$370M drag; Greater China only growth segment, +8% to $2.33B
- Gross margin 35% vs 38%; adjusted gross margin 56% vs 58%; operating loss $(2.66B) vs near-breakeven $10M in 2024, driven by $2.94B goodwill impairment
- Best segment: Greater China +8% constant currency; worst: JANZ -11% ($152M decline) from government price cuts and Indore impact
- Operating cash flow $2.32B (up $13M YoY); capex $378.8M; buybacks $500.5M; dividends $561.2M; 2026 capex guided $350M–$450M
- 2026 restructuring program targets $600M–$700M savings, $700M–$850M pre-tax charges; Nashik plant fire (Feb 2026) adds supply risk; biosimilar non-compete expiry unlocks new revenue opportunity
AI summary of the VTRS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Total revenues $3.76B vs $3.58B, up 5% YoY
- Greater China strongest segment, net sales $713.8M, up 21% YoY
- Emerging Markets weakest segment, net sales $542.3M, down 2% YoY
Risk Factors
- No material changes from Viatris’ 2025 Form 10-K risk factors
- Carried-forward risks not detailed in the provided excerpt
AI summary of the VTRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Conference call and webcast scheduled for 8:30 a.m. ET
- Discussion covers Viatris financial results for period ended June 30, 2026
Item 2.02: Results of Operations and Financial Condition
- Viatris reported financial results for the period ended June 30, 2026
- Press release issued August 6, 2026, with detailed results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $3.8B, up 3.5% operationally; adjusted EBITDA $1.2B, up 8%, signaling improving core execution
- GAAP net loss $119M, driven primarily by a $177.8M non-cash Tyrvaya impairment tied to its planned sale
Item 1.01: Entry into a Material Definitive Agreement
- ¥40 billion senior unsecured term loan refinances Viatris’ prior ¥40 billion facility, indicating debt rollover rather than incremental borrowing
- Initial interest rate TIBO plus 1.10%, with pricing adjustable based on Viatris’ credit ratings
Item 1.01: Entry into a Material Definitive Agreement
- €650 million raised via 4.250% senior unsecured notes due June 17, 2033
- Proceeds primarily refinance $1.675 billion of 3.950% notes maturing in 2026
AI summaries of VTRS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VTRS
Don't miss the next VTRS filing
- Alerts as it files. A push when VTRS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VTRS, by share count.
- Ask anything. An AI agent that reads every VTRS filing and answers with sources.
VTRS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Groothuis Leo Frans | A | Sep 30, 2026 | 2,469 | $17.72 |
| SIMMONS DAVID S | A | Sep 30, 2026 | 2,117 | $17.72 |
| Enrietti Andrew | M | Aug 15, 2026 | 999 | - |
| Enrietti Andrew | F | Aug 15, 2026 | 435 | $16.23 |
| Enrietti Andrew | F | Aug 15, 2026 | 10,931 | $16.23 |
| Enrietti Andrew | M | Aug 15, 2026 | 998.364 | - |
| Enrietti Andrew | M | Aug 15, 2026 | 25,134 | - |
| Enrietti Andrew | M | Aug 15, 2026 | 25,134 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $14.7B | $14.3B |
| Gross Profit | - | $5.6B | $5.0B |
| Operating Income | - | $10.1M | -$2.7B |
| Net Income | - | -$634.2M | -$3.5B |
| Gross Margin | - | 38.3% | 35.2% |
| Op. Margin | - | 0.1% | -18.7% |
| Net Margin | - | -4.3% | -24.7% |
| Balance Sheet | |||
| Total Assets | $47.7B | $41.5B | $37.2B |
| Equity | $20.5B | $18.6B | $14.7B |
| ROE | - | -3.4% | -23.9% |
| Per Share | |||
| EPS | - | $-0.53 | $-3.00 |
| Cash Flow | |||
| Operating CF | - | $2.3B | $2.3B |
| CapEx | - | $326.0M | $378.8M |
Source: XBRL data in Viatris (VTRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate VTRS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 48 | $9.48B |
| Q1 2026 | 46 | $7.15B |
| Q4 2025 | 40 | $6.98B |
| Q3 2025 | 41 | $5.67B |
| Q2 2025 | 42 | $4.87B |
| Q1 2025 | 36 | $3.17B |
| Q4 2024 | 34 | $4.13B |
| Q3 2024 | 32 | $2.05B |
- FMR LLC (Fidelity)+80.07M (+483%)
- T. Rowe Price Group+2.35M (+4%)
- BlackRock+1.66M (+2%)
- JPMorgan Chase & Co+1.59M (+28%)
- Vanguard Capital Management LLC+1.33M (+2%)
- Dimensional Fund Advisors−8.34M (-22%)
- Citadel Advisors LLC−3.49M (-87%)
- D.E. Shaw & Co−3.09M (-80%)
- Millennium Management−2.45M (-89%)
- AQR Capital Management−1.65M (-26%)
- Blackstone Group+52.5K
- WESTWOOD HOLDINGS GROUP INC+19.0K
- NICOLET BANKSHARES INC+13.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 319 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VTRS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 6, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 15, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Apr 16, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
VTRS SEC filings: frequently asked questions
Which institutions hold VTRS stock?
As of June 30, 2026, the largest Viatris (VTRS) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($1.5 billion), BlackRock ($1.4 billion), Vanguard Capital Management LLC ($1.2 billion), T. Rowe Price Group ($1.1 billion), Vanguard Portfolio Management LLC ($862.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VTRS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Viatris (VTRS) reported revenue of $14.3 billion (down 3.0% from FY2024) and a net loss of $3.5 billion. Diluted EPS was -$3.00. The figures come from the XBRL data in the 10-K.
What are the main risks in VTRS's latest 10-K?
In the 10-K filed February 26, 2026, Viatris (VTRS) flagged: FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025. U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected. (AI summary of the Risk Factors section.)
What did VTRS report in its latest 8-K?
Viatris (VTRS) filed an 8-K on August 6, 2026 reporting Item 8.01 (Other Events) and Item 2.02 (Results of Operations and Financial Condition). Conference call and webcast scheduled for 8:30 a.m. ET.
What are the latest VTRS SEC filings?
Viatris (VTRS) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on October 2, 2026.
What is VTRS's SEC CIK number?
Viatris (VTRS)'s SEC Central Index Key (CIK) is 1792044. EDGAR lists every VTRS filing under that number.
Ask anything about VTRS
The research agent reads VTRS's filings, financials, insider trades and 13F holders, then answers with sources.